You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 复星医药AH股齐涨 子公司新药获批开展临床试验
格隆汇 10-14 14:06
格隆汇10月14日丨复星医药(2196.HK)现报36.05港元,涨3.74%,暂成交2.9亿港元,最新H股市值923亿港元;复星医药(600196.SH)现报61.28元,涨4.13%,暂成交51亿元,最新A股市值1570亿元。复星医药昨日盘后发公告称,控股子公司复星医药产业收到国家药品监督管理局关于同意其获许可的马来酸阿伐曲泊帕片开展临床试验的通知书。该药品用于成人慢性免疫性血小板减少症适应症(ITP),复星医药产业拟于近期条件具备后于中国境内开展该新药针对该适应症的III期临床试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account